UG Healthcare Corp. Ltd. (8K7) AI Stock Analysis

• Market Cap: S$51.78M
• Dividend Yield: N/A
• Average Volume (3M): 131.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 25.06%
• EPS Growth: 37.11%
• Country: SG
• Employees: 898
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 623,825,800
• 10 Day Avg. Volume: 276,890
• 30 Day Avg. Volume: 131,003
• PEG Ratio: 0.48
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 0.47
• P/FCF Ratio: -8.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: S$0.08 ▼(-17.00% Downside)
• Action: Upgraded Date: 01/28/26
• Date: Action: Upgraded 01/28/26

The score is primarily held back by weak profitability and deteriorating cash flow despite strong revenue growth, with only partial support from a relatively stable balance sheet. Technicals are moderately positive with price above major moving averages, but valuation is constrained by a negative P/E and lack of dividend data.

Positive Factors

Revenue Growth

Sustained double-digit top-line expansion indicates durable demand for gloves and infection-prevention products, enhancing pricing power and scale. Over 2–6 months this growth can fund capacity utilization, amortize fixed costs, and support reinvestment if margins stabilize.

Capital Structure Stability

Moderate leverage and a strong equity base provide financial resilience against cyclical demand swings and commodity input volatility. This structural stability supports access to credit, capacity investment, and buffers short-term shocks without forcing distressed asset sales.

Vertically Diverse Model

Owning both manufacturing and distribution channels lets the company capture manufacturing margins and control supply reliability. Vertical integration supports margin recovery, channel diversification, and resilience to supplier or logistics disruptions over the medium term.

Negative Factors

Negative Profitability

Persistent negative margins mean sales growth is not translating into profits, signaling structural cost or pricing issues. Over months this undermines retained earnings, limits reinvestment capacity, and makes achieving sustainable returns dependent on material cost control or pricing recovery.

Deteriorating Cash Generation

A steep decline in free cash flow reduces the firm's ability to fund working capital, capex, and debt service from operations. Persistently weak cash generation increases reliance on external financing and raises execution risk for growth and margin-improvement plans in the medium term.

Negative Return on Equity

Negative ROE indicates the company is destroying shareholder value despite a sizable equity base. This reflects operational inefficiencies or pricing pressure and suggests management faces structural challenges in converting equity into sustainable profits over the coming quarters.

UG Healthcare Corp. Ltd. Business Overview & Revenue Model

Company Description

UG Healthcare Corp. Ltd. (8K7) is a prominent player in the healthcare sector, primarily focused on the manufacturing and distribution of medical gloves and other healthcare-related products. The company operates in various markets, providing essential products to hospitals, clinics, and healthcare providers worldwide. With a commitment to quality and innovation, UG Healthcare has established a strong reputation for its nitrile and latex gloves, catering to both the medical and industrial sectors.

How the Company Makes Money

UG Healthcare Corp. Ltd. generates revenue through the sale of its core products, primarily medical gloves, which are sold to healthcare facilities, distributors, and retailers globally. The company benefits from a diversified revenue model that includes both direct sales and partnerships with key distributors in various regions. Additionally, UG Healthcare leverages economies of scale in its manufacturing processes, allowing for competitive pricing and increased profit margins. The company's focus on quality assurance and compliance with international standards further enhances its market position, attracting long-term contracts and repeat business from clients. Significant partnerships with healthcare institutions and suppliers also contribute to its earnings, providing a steady stream of revenue.

UG Healthcare Corp. Ltd. Financial Statement Overview

Summary

Strong revenue growth (51.77%) is outweighed by weak profitability (net margin -2.63%, EBIT margin -0.87%) and pressured cash generation (free cash flow growth -78.07% and negative operating cash flow to net income ratio). Balance sheet is comparatively steadier with moderate leverage (debt-to-equity 0.30) and a strong equity base (equity ratio 68.33%), but negative ROE (-2.39%) remains a concern.

Income Statement

UG Healthcare Corp. Ltd. has experienced significant revenue growth of 51.77% in the latest year, indicating strong sales performance. However, the company is facing profitability challenges, with a negative net profit margin of -2.63% and an EBIT margin of -0.87%. This suggests that despite increasing revenues, the company is struggling to convert sales into profits, potentially due to high operating costs or other inefficiencies.

Balance Sheet

The company's debt-to-equity ratio of 0.30 indicates a moderate level of leverage, which is relatively stable compared to previous years. However, the return on equity is negative at -2.39%, reflecting the company's inability to generate positive returns for shareholders. The equity ratio stands at 68.33%, suggesting a strong equity base relative to total assets, which provides some financial stability.

Cash Flow

UG Healthcare Corp. Ltd. has a negative free cash flow growth rate of -78.07%, indicating a significant decline in cash generation. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. However, the free cash flow to net income ratio of 1.70 suggests that the company is generating more free cash flow relative to its net income, which could be a positive sign if sustained.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	94.93M	144.07M	115.20M	101.13M	232.60M	338.40M
Gross Profit	3.43M	34.74M	25.87M	1.45M	84.39M	196.16M
EBITDA	-21.20M	2.47M	-3.94M	-23.97M	53.37M	163.04M
Net Income	-20.93M	-3.79M	-6.06M	-20.73M	36.80M	118.77M
Balance Sheet
Total Assets	215.39M	232.35M	226.45M	230.00M	288.04M	268.29M
Cash, Cash Equivalents and Short-Term Investments	45.13M	23.29M	28.00M	61.74M	100.22M	68.44M
Total Debt	28.46M	47.36M	43.72M	31.13M	17.98M	16.74M
Total Liabilities	44.08M	76.03M	65.17M	48.81M	52.98M	73.53M
Stockholders Equity	171.94M	158.73M	163.39M	180.84M	228.90M	190.64M
Cash Flow
Free Cash Flow	-36.98M	-8.11M	-20.71M	-47.17M	31.63M	61.47M
Operating Cash Flow	-34.35M	-4.78M	-18.16M	-39.14M	53.95M	81.16M
Investing Cash Flow	-2.63M	-3.21M	-22.73M	-8.03M	-21.19M	-18.89M
Financing Cash Flow	4.62M	3.24M	8.36M	8.70M	-973.00K	-3.14M

UG Healthcare Corp. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8K7, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 23.44 is Positive, neither overbought nor oversold. The STOCH value of 19.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8K7.

UG Healthcare Corp. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AP4	74 Outperform	S$1.10B	20.33	14.10%	8.70%	4.74%	-17.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8K7	49 Neutral	S$51.78M	―	-2.33%	―	25.06%	37.11%